ArticleFrontiers in allergy2025
A shared metabolic-immune axis links local and systemic inflammation in chronic rhinosinusitis with comorbid asthma.
Article in Frontiers in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-omics and machine learning identify ALOX5 as a ferroptosis-associated driver of epithelial barrier dysfunction in chronic rhinosinusitis with nasal polyps.The World Allergy Organization journal · 2026Article
- Clinical and Cost-Effectiveness of Omalizumab in Concomitant Asthma and Chronic Rhinosinusitis with Nasal Polyps: A Real-World Exploratory Study.Journal of asthma and allergy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) comorbid with asthma (CRSwA) represents a severe "unified airway" phenotype, yet the metabolic mechanisms linking upper and lower airway inflammation remain unclear. This study aimed to identify shared metabolic signatures connecting local pathology with systemic circulation by comparing the metabolic profiles of nasal polyp tissue and serum. Methods: We performed an integrated analysis using non-targeted metabolomics and transcriptomics on paired nasal polyp tissue and serum samples from 22 CRSwA patients and 40 non-asthmatic CRSwNP patients to identify differential metabolites and explore their association with the immune microenvironment. Results: CRSwA patients exhibited distinct metabolic signatures dominated by lipids and their derivatives in both tissue and serum. An analysis of the metabolome shared between compartments revealed a weak but significant positive correlation in metabolic fold changes, suggesting a subtle systemic link to the local inflammation. This shared metabolic profile was strongly associated with a local Th2-polarized immune microenvironment. This shared profile was strongly associated with a local Th2-polarized immune microenvironment, where key metabolites (e.g., Resolvin D2, Lipoxin A4) correlated significantly with the abundance of M2 macrophages and eosinophils. Furthermore, a logistic regression model based on serum metabolites effectively distinguished CRSwA from non-asthmatic CRSwNP (AUC = 0.8322). Conclusion: Our study reveals a highly conserved "metabolic-immune axis" that connects local tissue inflammation with systemic circulation, positioning metabolic dysregulation as a central hub in the unified airway disease model for CRSwA. These findings offer new perspectives for developing serum-based diagnostic markers and metabolically-targeted therapies for this challenging clinical condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.